Share price · LXRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LXRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+10.6%
- 9 Oct 2026-4.5%
Nothing announced by LXRX that day or the session before.
- 24 Sep 2026-9.7%
Nothing announced by LXRX that day or the session before.
- 30 Jun 2026-9.1%
Nothing announced by LXRX that day or the session before.
- 26 Jun 2026+11.4%
Nothing announced by LXRX that day or the session before.
- 11 May 2026+15.5%
Nothing announced by LXRX that day or the session before.
- 8 May 2026+19.0%
- 19 Feb 2026+15.2%
Nothing announced by LXRX that day or the session before.
- 10 Feb 2026+9.2%
Nothing announced by LXRX that day or the session before.
- 30 Jan 2026-19.4%
Share of unusual movement by asset
For each asset, the share of LXRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | SGLT1/2 (dual)Small molecule | Heart FailureChronic Kidney DiseaseType 1 DiabetesHypertrophic Cardiomyopathy | |
| Phase 2 | AP2-associated kinase 1 (AAK1)Small molecule | Diabetic Peripheral Neuropathic Pain |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
January 2027 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $11M | $16M | $44M+ $139M short-term inv. | $14M-$8.1M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.7M | $17M | $41M+ $150M short-term inv. | $32M-$9.2M operating cash flow | report ↗ |
| 2026-Q1 | $21M | $13M | $67M+ $133M short-term inv. | $1.0M-$15M operating cash flow | report ↗ |
| 2025-Q3 | $14M | $19M | $79M+ $66M short-term inv. | $13M-$24M operating cash flow | report ↗ |
| 2025-Q2 | $29M | $16M | $50M+ $118M short-term inv. | —$17M operating cash flow | report ↗ |
| 2025-Q1 | $1.3M | $15M | $63M+ $132M short-term inv. | $25M-$44M operating cash flow | report ↗ |
| 2024-Q3 | $1.8M | $26M | $35M+ $224M short-term inv. | $65M-$54M operating cash flow | report ↗ |
| 2024-Q2 | $1.6M | $18M | $36M+ $274M short-term inv. | $53M-$49M operating cash flow | report ↗ |
| 2024-Q1 | $1.1M | $14M | $96M+ $259M short-term inv. | $48M-$55M operating cash flow | report ↗ |
| 2023-Q3 | $0.2M | $18M | $21M+ $197M short-term inv. | $51M-$42M operating cash flow | report ↗ |
| 2023-Q2 | $0.3M | $15M | $102M+ $154M short-term inv. | $45M-$38M operating cash flow | report ↗ |
| 2023-Q1 | <$0.1M | $12M | $26M+ $80M short-term inv. | $32M-$32M operating cash flow | report ↗ |
| 2022-Q3 | <$0.1M | $11M | $19M+ $117M short-term inv. | $23M-$19M operating cash flow | report ↗ |
| 2022-Q2 | <$0.1M | $13M | $21M+ $41M short-term inv. | $25M-$24M operating cash flow | report ↗ |
| 2022-Q1 | — | $15M | —+ $27M short-term inv. | $23M-$23M operating cash flow | report ↗ |
| 2021-Q3 | <$0.1M | $16M | —+ $29M short-term inv. | $23M-$17M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $50M | $61M | $63M+ $62M short-term inv. | $13M-$68M operating cash flow | report ↗ |
Lexicon Pharmaceuticals reported full-year 2025 revenue of $49.8M, up 60.2% YoY, with R&D spend of $61.12M, down 27.7% YoY. The company ended the year with $63.33M in cash and equivalents, or $125.2M including investments and restricted cash, and reported a net loss of $50.34M for the full year.
Lexicon stated that pivotal sotagliflozin milestones remain on schedule, including NDA resubmission in type 1 diabetes and enrollment completion of the SONATA-HCM Phase 3 study in mid-2026, with topline results expected in the first quarter of 2027; the study had surpassed 50% enrollment across 130 sites. A positive End-of-Phase 2 meeting with the FDA supports Phase 3 readiness for pilavapadin in diabetic peripheral neuropathic pain, and partnership discussions continue. The company also completed IND-enabling activities for LX9851, received a $10M milestone payment from Novo Nordisk in February 2026, and raised approximately $96.7M in net proceeds from a stock sale.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $31M | $84M | $67M+ $171M short-term inv. | $50M-$179M operating cash flow | report ↗ |
| 2023-FY | $1.2M | $59M | $22M+ $148M short-term inv. | $44M-$162M operating cash flow | report ↗ |
| 2022-FY | $0.1M | $53M | $46M+ $92M short-term inv. | $25M-$89M operating cash flow | report ↗ |
| 2021-FY | $0.3M | $55M | $64M+ $23M short-term inv. | $22M-$87M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 9 purchases ($2.8M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-06 | Exton Michael · director, Chief Executive Officer | Open-market purchase | 30,064 | $1.66 | $50K | Form 4 |
| 2026-06-03 | DEBBANE RAYMOND · director | Option exercise | 89,312 | — | — | Form 4 |
| 2026-06-03 | Amouyal Philippe · director | Option exercise | 89,312 | — | — | Form 4 |
| 2026-06-03 | BARKER SAM L · director | Option exercise | 89,312 | — | — | Form 4 |
| 2026-06-03 | Cheung Ivan · director | Option exercise | 89,312 | — | — | Form 4 |
| 2026-06-03 | SOBECKI CHRISTOPHER J · director | Option exercise | 89,312 | — | — | Form 4 |
| 2026-06-03 | Sullivan Diane E. · director | Option exercise | 89,312 | — | — | Form 4 |
| 2026-06-03 | Swain Judith L · director | Option exercise | 89,312 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 136 reporting institutions held 323.4M shares ($502.1M, 72.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Artal Group S.A. | 154,734,327 | $241.4M |
| 2 | FMR LLC | 45,056,338 | $70.3M |
| 3 | Siren, L.L.C. | 44,303,518 | $69.1M |
| 4 | Sessa Capital IM, L.P. | 17,912,961 | $27.9M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 9,519,167 | $14.8M |
| 6 | Point72 Asset Management, L.P. | 7,814,606 | $12.2M |
| 7 | MILLENNIUM MANAGEMENT LLC | 4,944,731 | $7.7M |
| 8 | BlackRock, Inc. | 3,322,219 | $5.2M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 3,169,111 | $4.9M |
| 10 | JANE STREET GROUP, LLC | 2,665,938 | $4.2M |
| 11 | UBS Group AG | 2,483,182 | $3.9M |
| 12 | MARSHALL WACE, LLP | 2,376,304 | $3.7M |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,121,164 | $3.3M |
| 14 | CIBC Bancorp USA Inc. | 1,800,000 | $2.8M |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 1,600,500 | $2.5M |